Saturday, April 20, 2024 4/20/2024

A Multi-Level Evaluation of California's New Medicaid Coverage for the Diabetes Prevention Program

Award Number: R18DK122372
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: KDA (KNOWLEDGE/DEVELOPMENT/APPLICATION)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

PROJECT SUMMARY/ABSTRACT The Diabetes Prevention Program (DPP) helps patients with prediabetes initiate lifestyle changes and delay or prevent T2DM. However, the DPP has been most successful in middle-class populations. The Centers for Disease Control and Prevention (CDC)-supported National Diabetes Prevention Program achieved widespread implementation but had limited reach and effectiveness in low-income communities. In a major step forward, California has mandated in Senate Bill 97 that as of January 1, 2019, all eligible Medicaid (e.g., Medi-Cal) beneficiaries who want to enroll in the DPP must be provided this opportunity. The outcomes of SB 97 will have major implications on diabetes prevention for Medicaid beneficiaries not only in California but also across the US. We are proposing an evaluation of SB 97 using data from Kaiser Permanente Northern California (KPNC) and the University of California, Los Angeles (UCLA). Using advanced analytic approaches, we will evaluate the effects of this natural experiment on clinical outcomes. We will also collect important contextual primary data from the 43 CDC-recognized or pending DPP suppliers in California, and from both DPP lifestyle coaches and DPP participants. Our Specific Aims are as follows: 1) To determine the effectiveness of SB 97 and mandated Medi-Cal DPP coverage on change in body weight (primary outcome), systolic blood pressure (SBP), uptake of the DPP in- person or online, and projected future cost savings (all secondary outcomes) among Medi-Cal beneficiaries with prediabetes at KPNC and UCLA, versus a comparison cohort of patients with insurance coverage from the California Health Insurance Exchange (HIE). 2) To characterize perspectives from leaders of CDC-recognized DPP suppliers including decisions about providing DPP to Medi-Cal beneficiaries, such as their processes of identifying the target population, raising awareness of and promoting the DPP, and recruiting and enrolling eligible participants. 3) To characterize perspectives of Medi-Cal DPP participants and DPP lifestyle coaches on facilitators and barriers to participant retention and engagement. Our team includes a collaborative group of health services researchers, a statistician, and a health economist with experience in program evaluation and outcomes research, who have a longstanding working relationship. If funded, we are well positioned and ready to initiate the proposed policy evaluation in the post-enactment period.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $712,191 )
2023	2023	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	6/29/2023	NON-COMPETING CONTINUATION	$569,393
2023	2023	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	4	7/1/2023	SUPPLEMENT FOR EXPANSION	$142,798
														Subtotal = $712,191

Issue Date FY: 2022 ( Subtotal = $726,551 )
2022	2022	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	6/9/2022	NON-COMPETING CONTINUATION	$577,253
2022	2022	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	6/13/2022	SUPPLEMENT FOR EXPANSION	$149,298
														Subtotal = $726,551

Issue Date FY: 2021 ( Subtotal = $587,266 )
2021	2021	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	6/29/2021	NON-COMPETING CONTINUATION	$587,266
														Subtotal = $587,266

Issue Date FY: 2020 ( Subtotal = $609,553 )
2020	2020	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90095	LOS ANGELES	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	7/27/2020	NEW	$609,553
														Subtotal = $609,553

Grand Total All Awards = $2,635,561

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Multi-Level Evaluation of California's New Medicaid Coverage for the Diabetes Prevention Program

Award Number: R18DK122372

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: KDA (KNOWLEDGE/DEVELOPMENT/APPLICATION)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer